Match!

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Published on Nov 1, 2017in Molecular Cancer Research4.48
· DOI :10.1158/1535-7163.MCT-17-0386
Aaron M. Goodman9
Estimated H-index: 9
(UCSD: University of California, San Diego),
Shumei Kato12
Estimated H-index: 12
(UCSD: University of California, San Diego)
+ 6 AuthorsRazelle Kurzrock99
Estimated H-index: 99
(UCSD: University of California, San Diego)
Abstract
Immunotherapy induces durable responses in a subset of patients with cancer. High TMB may be a response biomarker for PD-1/PD-L1 blockade in tumors such as melanoma and non-small cell lung cancer (NSCLC). Our aim was to examine the relationship between TMB and outcome in diverse cancers treated with various immunotherapies. We reviewed data on 1,638 patients who had undergone comprehensive genomic profiling and had TMB assessment. Immunotherapy-treated patients (N = 151) were analyzed for response rate (RR), progression-free and overall survival (PFS, OS). Higher TMB was independently associated with better outcome parameters (multivariable analysis). The RR for patients with high (≥ 20 mutations/mb) vs. low to intermediate TMB was 22/38 (58%) vs. 23/113 (20%) (P = 0.0001); median PFS, 12.8 vs. 3.3 months (P =
Figures & Tables
  • References (51)
  • Citations (302)
References51
Newest
#1Zachary R. Chalmers (Foundation Medicine)H-Index: 13
#2Caitlin Connelly (Foundation Medicine)H-Index: 4
Last.Garrett M. Frampton (Foundation Medicine)H-Index: 37
view all 23 authors...
#1Amélie Boichard (UCSD: University of California, San Diego)H-Index: 4
#2Igor Tsigelny (UCSD: University of California, San Diego)H-Index: 34
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 3 authors...
#1Yulian Khagi (UCSD: University of California, San Diego)H-Index: 2
#2Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
Last.Sandip Pravin Patel (UCSD: University of California, San Diego)H-Index: 16
view all 3 authors...
#1Wenqiang Ma (UMN: University of Minnesota)H-Index: 2
#2Shi-Hua Li (CAS: Chinese Academy of Sciences)H-Index: 13
Last.GeorgeFGaoH-Index: 73
view all 19 authors...
#1Claud Grigg (CUMC: Columbia University Medical Center)H-Index: 5
#2Naiyer A. Rizvi (CUMC: Columbia University Medical Center)H-Index: 57
#1Sadakatsu Ikeda (UCSD: University of California, San Diego)H-Index: 9
#2Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 9
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 9 authors...
#1Douglas B. Johnson (VUMC: Vanderbilt University Medical Center)H-Index: 40
#2Garrett M. Frampton (Foundation Medicine)H-Index: 37
Last.Christine M. Lovly (VUMC: Vanderbilt University Medical Center)H-Index: 33
view all 27 authors...
Cited By302
Newest
#1You Li (FDA: Food and Drug Administration)
#2Janaki Veeraraghavan (FDA: Food and Drug Administration)
Last.Reena Philip (FDA: Food and Drug Administration)H-Index: 10
view all 3 authors...
#1Hui Cai ('SMMU': Second Military Medical University)H-Index: 1
#2Changqing Jing (SDU: Shandong University)H-Index: 1
Last.Kai Yin ('SMMU': Second Military Medical University)H-Index: 1
view all 17 authors...
#1Hengrui Liang (Guangzhou Medical University)H-Index: 4
#2Zhichao Liu (Guangzhou Medical University)
Last.Wenhua Liang (Guangzhou Medical University)H-Index: 18
view all 9 authors...
View next paperNivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer